Meeting
2023 ASCO Annual Meeting
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.
Authors
Erika P. Hamilton
Sarah Cannon Research Institute at Tennessee Oncology, Nashiville, TN
Erika P. Hamilton , Miguel Martin , Ciara Catherine O'Sullivan , Giuseppe Curigliano , Joohyuk Sohn , Junji Tsurutani , Konstantinos Tryfonidis , Libero Santarpia , Shan Yang , Véronique Diéras
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT05132582
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS1115)
DOI
10.1200/JCO.2023.41.16_suppl.TPS1115
Abstract #
TPS1115
Poster Bd #
334a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress).
First Author: Erika P. Hamilton
Poster
2021 ASCO Annual Meeting
Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
First Author: Giuseppe Curigliano
First Author: Nicholas Patrick McAndrew
Poster
2021 ASCO Annual Meeting
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
First Author: Ian E. Krop